Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
NASDAQ:NKTR
Price:
1.32 USD
Market Closed
Updated:
Apr 29, 2024
Nektar Therapeutics
Cash from Operating Activities
|
Nektar Therapeutics
Cash from Operating Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Nektar Therapeutics
NASDAQ:NKTR
|
Cash from Operating Activities
-$192.6m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-17%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
15%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$13B
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
See Also
What is Nektar Therapeutics's Cash from Operating Activities?
Cash from Operating Activities
-192.6m
USD
-192.6m
USD
Based on the financial report for Dec 31, 2023, Nektar Therapeutics's Cash from Operating Activities amounts to -192.6m USD.
What is Nektar Therapeutics's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-17%
-17%
Over the last year, the Cash from Operating Activities growth was 37%. The average annual Cash from Operating Activities growth rates for Nektar Therapeutics have been 15% over the past three years , and -17% over the past ten years .
You don't have any saved screeners yet
